TY - JOUR
T1 - Improved cognition, mild anxiety-like behavior and decreased motor performance in pyridoxal phosphatase-deficient mice
AU - Jeanclos, Elisabeth
AU - Albersen, Monique
AU - Ramos, Rúben J.J.
AU - Raab, Annette
AU - Wilhelm, Christian
AU - Hommers, Leif
AU - Lesch, Klaus Peter
AU - Verhoeven-Duif, Nanda M.
AU - Gohla, Antje
N1 - Funding Information:
We thank Angelika Keller and Kerstin Hadamek for excellent technical assistance, and Heinrich Blazyca and Drs. Dennis Klein and Rudolf Martini for generous help with grip strength measurements. Marjolein Bosma is thanked for the analysis of B6 vitamers. We acknowledge the assistance of Charlotte Auth and Gabriel Christmann with immunoblots. This work was supported by the Deutsche Forschungsgemeinschaft SFB728 and SFB688 (to AG) and the IZKF Würzburg (to LH). CW was supported by a predoctoral fellowship from the Medical Faculty of the University of Würzburg (Graduate School of Life Sciences) and by a Kaltenbach predoctoral fellowship from the German Heart Foundation .
Funding Information:
We thank Angelika Keller and Kerstin Hadamek for excellent technical assistance, and Heinrich Blazyca and Drs. Dennis Klein and Rudolf Martini for generous help with grip strength measurements. Marjolein Bosma is thanked for the analysis of B6 vitamers. We acknowledge the assistance of Charlotte Auth and Gabriel Christmann with immunoblots. This work was supported by the Deutsche Forschungsgemeinschaft SFB728 and SFB688 (to AG) and the IZKF W?rzburg (to LH). CW was supported by a predoctoral fellowship from the Medical Faculty of the University of W?rzburg (Graduate School of Life Sciences) and by a Kaltenbach predoctoral fellowship from the German Heart Foundation.
Publisher Copyright:
© 2018 The Authors
PY - 2019/1
Y1 - 2019/1
N2 - Pyridoxal 5′-phosphate (PLP) is an essential cofactor in the catalysis of ~140 different enzymatic reactions. A pharmacological elevation of cellular PLP concentrations is of interest in neuropsychiatric diseases, but whole-body consequences of higher intracellular PLP levels are unknown. To address this question, we have generated mice allowing a conditional ablation of the PLP phosphatase PDXP. Ubiquitous PDXP deletion increased PLP levels in brain, skeletal muscle and red blood cells up to 3-fold compared to control mice, demonstrating that PDXP acts as a major regulator of cellular PLP concentrations in vivo. Neurotransmitter analysis revealed that the concentrations of dopamine, serotonin, epinephrine and glutamate were unchanged in the brains of PDXP knockout mice. However, the levels of γ-aminobutyric acid (GABA) increased by ~20%, demonstrating that elevated PLP levels can drive additional GABA production. Behavioral phenotyping of PDXP knockout mice revealed improved spatial learning and memory, and a mild anxiety-like behavior. Consistent with elevated GABA levels in the brain, PDXP loss in neural cells decreased performance in motor tests, whereas PDXP-deficiency in skeletal muscle increased grip strength. Our findings suggest that PDXP is involved in the fine-tuning of GABA biosynthesis. Pharmacological inhibition of PDXP might correct the excitatory/inhibitory imbalance in some neuropsychiatric diseases.
AB - Pyridoxal 5′-phosphate (PLP) is an essential cofactor in the catalysis of ~140 different enzymatic reactions. A pharmacological elevation of cellular PLP concentrations is of interest in neuropsychiatric diseases, but whole-body consequences of higher intracellular PLP levels are unknown. To address this question, we have generated mice allowing a conditional ablation of the PLP phosphatase PDXP. Ubiquitous PDXP deletion increased PLP levels in brain, skeletal muscle and red blood cells up to 3-fold compared to control mice, demonstrating that PDXP acts as a major regulator of cellular PLP concentrations in vivo. Neurotransmitter analysis revealed that the concentrations of dopamine, serotonin, epinephrine and glutamate were unchanged in the brains of PDXP knockout mice. However, the levels of γ-aminobutyric acid (GABA) increased by ~20%, demonstrating that elevated PLP levels can drive additional GABA production. Behavioral phenotyping of PDXP knockout mice revealed improved spatial learning and memory, and a mild anxiety-like behavior. Consistent with elevated GABA levels in the brain, PDXP loss in neural cells decreased performance in motor tests, whereas PDXP-deficiency in skeletal muscle increased grip strength. Our findings suggest that PDXP is involved in the fine-tuning of GABA biosynthesis. Pharmacological inhibition of PDXP might correct the excitatory/inhibitory imbalance in some neuropsychiatric diseases.
KW - Motor performance
KW - Neuropsychiatric diseases
KW - Neurotransmitter biosynthesis
KW - Pyridoxal phosphatase
KW - Vitamin B6
KW - γ-Aminobutyric acid (GABA)
UR - https://www.scopus.com/pages/publications/85051696706
U2 - 10.1016/j.bbadis.2018.08.018
DO - 10.1016/j.bbadis.2018.08.018
M3 - Article
C2 - 30327125
AN - SCOPUS:85051696706
SN - 0925-4439
VL - 1865
SP - 193
EP - 205
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 1
ER -